Circulating tumor DNA analysis has several potential applications in cancer diagnostics. However, results in literature vary considerably, often due to different blood collection methods and protocols. Several new products to address pre-analytical variables of cfDNA processing have recently become available, and little is understood about their effects on DNA quality and downstream applications. We evaluated the effects of blood collection protocols and DNA extraction kits on cfDNA yield, quality, and fragment size using droplet-digital PCR (ddPCR) and targeted deep sequencing.
Download count: 0